Palisade Bio (PALI) announced the appointment of Brian Feagan, MD, FRCPC, to its Clinical Advisory Board. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on PALI: Palisade Bio announces preliminary results from Phase 1 study of PALI-2108 Palisade Bio to present preclinical results for PALI-2108 Palisade Bio initiated with a Buy at Brookline Palisade Bio price target lowered to $8 from $22.50 at Maxim Palisade Bio reports Q3 EPS ($2.32) vs. ($7.38) last year